$OURA

Eli Lilly's partnership with Counsel Health for GLP-1 prescriptions may be affected by Oura's acquisition of Counsel. Lilly could gain a financial stake in Oura, with a $50 million stock purchase contingent on certain conditions, though these have not yet been met, according to STAT's Elaine Chen.

Oura Health agreed to acquire Counsel Health for $625 million in cash, representing 36% of Oura's last fiscal year's revenue. Counsel provides AI-driven medical chat with licensed doctors, enhancing Oura's smart ring capabilities. The deal is expected to close by the end of 2026, subject to conditions. Oura aims to integrate Counsel's services to offer more comprehensive health solutions, potentially boosting membership retention and IPO prospects.

Entegris acquired Advanced Abrasives to expand semiconductor materials for AI chips, investing in Taiwan manufacturing. Siemens agreed to buy Lauterbach for $1.6B to bolster semiconductor design and verification. Oura will acquire Counsel Health for $625M to combine biometric data with AI-powered medical care. Cribl acquired Tero to enhance AI observability and monitoring capabilities.

Oura to buy AI healthcare startup Counsel Health for $625M, expanding its services. Oura postponed its IPO, citing market uncertainty. Counsel's AI platform integrates with Oura's app, offering medical advice and physician access. Oura's Q3 revenue grew 153% YoY to $533M, with FY2026 revenue at $1.75B, up 92% YoY.

The US DOJ and states sued Apple in March 2024 for alleged antitrust violations. Apple subpoenaed companies like Epic Games, Samsung, and Meta for evidence. The DOJ also subpoenaed firms including Roblox and Snap. Disputes arise over subpoena scope and requested documents. Companies like Epic and Oura object to Apple's requests, citing burden and trade secrets. Apple seeks documents from federal agencies, with a special master siding with Apple twice. (350 characters)

Oura, a smart-ring maker, postponed its $2.2bn IPO on 29 September 2026 due to market uncertainty. The offering included 50 million shares priced between $40 and $44, with most proceeds going to existing investors. Oura planned to use its share for employee tax obligations. The company reported strong revenue growth and profitability but faces market and legal risks. No new IPO date has been set.

Ouraring Inc. sued Ultrahuman and SVTronics Inc. for patent infringement in the U.S. District Court for the Eastern District of Texas, alleging Ultrahuman's Ring Pro infringes its design and utility patents. Oura seeks injunctive relief and damages, including treble damages for willful infringement. This follows an earlier ITC ruling excluding Ultrahuman's Ring Air from the U.S. market.

Oura filed a patent infringement lawsuit against Ultrahuman in the U.S. District Court for the Eastern District of Texas, alleging that Ultrahuman's redesigned smart ring still infringes on Oura's patents, including design and utility patents. This follows a 2025 ITC ruling that barred Ultrahuman's original smart rings from being imported into the U.S.

Oura and MD Live are partnering on a GLP-1 program, starting in early 2027, offering Oura Rings and clinical care to select employer health plans. The program tracks medication, symptoms, and health metrics, with optional data sharing with clinicians. Oura's existing GLP-1 Insights feature has 260,000 U.S. members, with 80% continuing to record doses after three months.

Oura, a smart-ring company, has reached 6 million paying members, adding 1 million since June. The company is reassessing its IPO timing, according to the Wall Street Journal.